Financing channel feed – Endpoints News

Financing channel feed

Clementia keeps the biotech IPO party going with $120M play on an upsized offering

8 years ago

Amplyx grabs $67M to fund a pivotal drive to the FDA with an anti-fungal aimed at a lethal threat

8 years ago

Milestone Pharma preps a leap into PhIII cardio study with $55M round backed by Novo

8 years ago

A fast-moving entry in the gene editing race is speeding to the clinic, fueled by an $83.5M round

8 years ago

Sienna Bio bags $65M in the latest successful biotech IPO

8 years ago

British billionaire Jim Mellon and high-profile partners roll the dice on an anti-aging upstart

8 years ago

Canaan reels in a jumbo $800M fund with a big focus on a new wave of biotech startups

8 years ago

Riders on the storm: VenatoRx bags a $42M round to back antibiotics pipeline

8 years ago

Lilly, J&J, AbbVie and WuXi help seed a regenerative medicine upstart

8 years ago

Backed by partners at Pfizer, eFFECTOR brings its VC total to $150M as PhII cancer trial looms

8 years ago

Langer-backed Kala scores $90M IPO as it lines up a pair of NDAs

8 years ago

What's holding back biotech M&A? SVB tracks a trend and calls a comeback

8 years ago

With help from Novartis and Sanofi, NeuroVia heads to the clinic armed with a $14M round

8 years ago

Clarus readies a slate of big PhIII risk-sharing bets with a new $910M fund

8 years ago

Akcea IPO stumbles and falls well below the range, but still raises $175M

8 years ago

Ocular Therapeutix's last-minute gambit fails to salvage its second FDA application, shares plunge

8 years ago

Big Pharma VCs jump in to back a $63M mission to tackle a genetic driver of Alzheimer’s

8 years ago

After raising $100M, Google-backed Evelo looks to blaze a new trail with monoclonal microbials

8 years ago

Zealand Pharma blueprints an $86M IPO on Nasdaq as it maneuvers its way into PhIII

8 years ago

Google’s data-crunching mavens at GV buy in to Decibel’s R&D program for hearing loss, tinnitus

8 years ago

Medicxi’s new fund jumps off the beaten biotech path to lead a $30M round for diabetes program

8 years ago

Fast-moving Sienna Bio vaults from buyout to B round to $75M IPO

8 years ago

Another biotech IPO boasting a pharma castoff rings the bell on Wall Street with $75M haul

8 years ago

Atlas Venture vows to keep doing well by doing good with its new, $350M biotech fund

8 years ago

First page Previous page 138 139 140141142 143 144 Next page Last page